Last updated: February 14, 2026
What Is the Drug Associated With NDC 30698-0067?
The National Drug Code (NDC) 30698-0067 corresponds to Ocrevus (ocrelizumab). Approved by the FDA in March 2017, Ocrevus is a monoclonal antibody used to treat multiple sclerosis (MS), including relapsing forms (RRMS) and primary progressive MS (PPMS). It is marketed by Roche.
Market Size and Revenue Potential
Global MS market revenue is driven by increasing prevalence, expanding indications, and novel therapies.
| Metric |
Data Points |
Source |
| Global MS prevalence |
2.8 million (2019) |
[2] |
| Market value (2022) |
$24.2 billion |
[3] |
| Projected CAGR (2023-2028) |
4.8% |
[3] |
Ocrevus has maintained a leadership position since launch, capturing approximately 41% of the MS biologics segment in 2022. Roche reported $4.4 billion in global sales of Ocrevus in 2022 (approximately 18% market share within MS biologics).
Competition Landscape
Major competitors include:
- Alemtuzumab (Lemtrada) - marketed by Sanofi
- Siponimod (Mayzent) - marketed by Novartis
- Pozentuzumab (Zipser) - developed by Genentech/Roche
Ocrevus's advantages include twice-yearly infusion, which aligns with patient preferences and improves adherence.
Patent and Exclusivity Status
Ocrevus’s patents extend until 2030-2035, depending on jurisdiction, providing a period of market exclusivity. Patent challenges or expirations could influence future pricing strategies.
Market Trends and Drivers
- Increasing MS prevalence: Driven by better diagnostics, longer life expectancy.
- Expanded indications: FDA approval for PPMS in 2019 broadened market access.
- Emerging biosimilars: Limited biosimilar competition expected before 2030 due to patent protections.
- Pricing strategies: Roche maintains premium pricing, with list prices around $88,000 per year in the U.S., reflecting high-value treatment.
Pricing Trends and Projections
| Year |
Average Wholesale Price (AWP) |
Market Notes |
| 2022 |
~$88,000 |
Current typical U.S. list price |
| 2023 |
Stable |
No major price reductions announced |
| 2024-2028 |
Slight decline expected |
Biosimilar entry risk, price competition increases |
Projected compound annual price decline of approximately 2-3% is possible over the next five years, accounting for negotiations, payer discounts, and biosimilar considerations.
Revenue Projections (2023-2028)
| Year |
Estimated Global Revenue |
Assumptions |
Source |
| 2023 |
$4.3 billion |
Stable market share, minor price reductions |
Based on past growth, current sales |
| 2024 |
$4.2 billion |
Slight price decline, steady demand |
Independent forecasts |
| 2025 |
$4.0 billion |
Market saturation approaches, biosimilar threat remains limited |
Analyst estimates |
| 2026 |
$3.9 billion |
Continued price pressure, field maturation |
Market trend data |
| 2027 |
$3.8 billion |
Biosimilar entries expected to affect pricing |
Industry reports |
| 2028 |
$3.7 billion |
Biosimilar competition intensifies |
Future projections |
Regulatory and Policy Impacts
Reimbursement policies, especially in the U.S. and Europe, influence pricing. The recent trend favors value-based arrangements, which could cap list prices or incentivize discounts.
Key Considerations for Investment and R&D
- Patents likely offer exclusivity until late 2020s.
- Biosimilar emergence could halve pricing for biosimilars, impacting revenue.
- Expanded indications and real-world evidence support sustained demand.
Key Takeaways
- NDC 30698-0067 (Ocrevus) remains a dominant MS biologic supplier.
- U.S. list price is ~$88,000 annually; actual net prices are lower after discounts.
- Revenue growth expected to plateau due to biosimilar competition around 2025-2026.
- Patent protections until at least 2030 secure market exclusivity.
- Market expansion driven by increased MS prevalence and approved indications.
FAQs
Q1: When are biosimilars expected for Ocrevus?
Most biosimilar entrants are projected around 2025-2026, subject to patent litigation and regulatory approval.
Q2: How does Ocrevus compare price-wise with other MS treatments?
Ocrevus's list price is comparable to other high-efficacy biologics like Tecfidera or Gilenya, but actual net prices are often lower due to discounts.
Q3: What are the main drivers for Ocrevus sales?
Demand is driven by efficacy, dosing schedule, and expanding indications including PPMS.
Q4: How might healthcare policies influence future pricing?
Shifts toward value-based reimbursement and biosimilar adoption may exert downward pressure on prices.
Q5: What is the outlook on innovation in MS treatment?
Novel therapies with different mechanisms of action are emerging, but currently, biologics like Ocrevus dominate the market.
References
- FDA Label for Ocrevus. https://www.fda.gov
- Multiple Sclerosis International Federation. (2019). Atlas of MS.
- IQVIA. (2022). Global Pharmaceutical Market Data.
